COMPANY PROFILE

Epiendo

Explore full profile

Develops drugs that target epithelial differentiation, regeneration, and barrier function

Reykjavík, IcelandFounded 2014Biotech & Life Sciences

Valuation $100–250M Last recorded · 2021

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Epiendo

Developer of drugs and proprietary compounds intended to offer new treatments for chronic airway diseases. The company specializes in developing novel and proprietary drugs that preserve the barrier-enhancing effects of azithromycin and uses a non-antibiotic macrolide platform that addresses epithelial dysfunction and other key drivers of inflammation in chronic respiratory diseases, enabling healthcare professionals to provide patients with the right treatment to improve their lives.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2014
Headquarters: Reykjavík, Iceland
Employees: 12
Open positions: None listed
Dealroom signal: 65.6/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Drug Development, Chronic Disease, Sustainable Development Goals, EIC, Biotech and Pharma, EIC Fund, Nordic Rising Star 2022, Horizon Europe
Business model: Manufacturing
Client focus: b2c
Links: Website LinkedIn X

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

10 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
CONVERTIBLE✓Equity / VC	Jan 2026	$9.9M	—	Undisclosed	↗
SERIES A✓Equity / VC	Aug 2021	$22M	$88M	Iðunn Venture Fund · ABC Ventures · EIC Fund · Flerie Invest	↗

Showing the latest 2 of 10 recorded eventsBook a demo for the full funding history →

Growth signals

Epiendo website traffic

Latest recorded traffic for Epiendo is 90 monthly website visits, down 25% over the last three months. Epiendo's team declined 7.7% over the past year.

Latest monthly visits90 3-month web change-25% 1-year team growth-7.7%

Monthly website visitsFeb 2016–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
IPIlya PharmaIlya Pharma develops immune-cell therapies. The company's biological medicine uses lactic acid bacteria as vectors to deliver biological drugs on-site to skin wounds or the GI tract	Uppsala kommun, Sweden	Operational	13	$15M	$22M
ANAntabioAntabio is a clinical-stage biopharmaceutical company developing novel antibacterials targeting drug-resistant pathogens that are deemed a critical priority by the WHO	Labège, France	Operational
AAAlginor ASAAlginor's green innovation, AORTA, increases the utilisation ratio of seaweeds from approximately 15 to 100% without using formaldehyde and other harmful chemicals	Haugesund, Norway	Operational
TBTILT BiotherapeuticsTILT Bio aims to enable T-cell treatments and immune checkpoint inhibitors with oncolytic viruses, used to boost lymphocytes and immunological checkpoint blocking antibody treatments	Helsinki, Finland	Operational
IRIris.aiAn AI based platform for R&D departments to make research documentation actionable	Bærum, Norway	Operational
ATArctic TherapeuticsTransforming drug discovery and development by harnessing the power of applied of genomics	Reykjavík, Iceland	Operational
QPQubit PharmaceuticalsQuantum physics and AI-driven drug discovery platform	Paris, France	Operational
NENeuroKaireGenetika+ is developing a tailored medical diagnostic instrument to help doctors cure depression. Genetika+ predicts the best pharmacological treatment for each patient, allowing faster treatment	Kearny, United States	Operational